An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Top results in this bookTable of Contents
Ustekinumab (Stelara) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
Certolizumab Pegol (Cimzia) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.
Reslizumab (Cinqair) [Internet].
Entyvio (Vedolizumab) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Dec.
Ustekinumab (Stelara) Injection [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.
Tocilizumab (Actemra, Intravenous): For the Treatment of Signs and Symptoms of Active Polyarticular Juvenile Idiopathic Arthritis in Patients Two Years of Age and Older Who Have Responded Inadequately to Previous Therapy With Disease-Modifying Antirheumatic Drugs and Systemic Corticosteroids [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug.
Ranibizumab (Lucentis): Visual Impairment due to Choroidal Neovascularization Secondary to Pathologic Myopia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet].
Denosumab (Xgeva) [Internet].
Clinical Review Report: sarilumab (Kevzara) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May.
Clinical Review Report: Burosumab (Crysvita): (Kyowa Kirin Limited): Indication: For the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jul.
Tocilizumab (Actemra): Adult Patients with Moderately to Severely Active Rheumatoid Arthritis [Internet].
Clinical Review Report: Omalizumab (Xolair) [Internet].
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec.
Clinical Review Report: Certolizumab Pegol (Cimzia): (UCB Canada Inc.): Indication: Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan.
Denosumab (Prolia): Treatment to Increase Bone Mass in Men with Osteoporosis at High Risk for Fracture; or Who Have Failed or are Intolerant to Other Available Osteoporosis Therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Oct.
Clinical Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz can be used alone or in combination with a conventional DMARD (e.g., methotrexate) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.
Clinical Review Report: adalimumab (Humira) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr.
Clinical Review Report: Daclizumab (Zinbryta) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jul.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on